A Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NTRX-07 in Subjects With Mild Cognitive Impairment or Mild to Moderate Alzheimer's Disease

1. Study Overview NeuroTherapia Inc. is conducting a clinical study to explore the safety and effects of a new drug called NTRX- 07. This drug targets people with mild cognitive impairment (MCI) or mild to moderate Alzheimer's disease (AD). The study's primary focus is on safety and how the drug interacts with the body over a short-term period of 28 days. This research is important as it aims to find new ways to manage symptoms and slow the progression of AD.
2. Key Objectives Primary Objective:
* To assess the safety and tolerability of NTRX-07 in patients with AD.
* Safety and tolerability will be measured by monitoring any side effects or adverse events in participants during and after the treatment period.
Secondary Objective:
* To study how NTRX-07 is processed by the body, including how it is absorbed, distributed, metabolized, and eliminated.
* This includes measuring the drug levels in the blood and cerebrospinal fluid (CSF) over time.
3. Study Design ? Type of Study:
o A randomized, double-masked, placebo-controlled study. "Randomized" means participants are randomly assigned to receive either the actual drug (NTRX-07) or a placebo (an inactive substance). "Double-masked" indicates that neither the participants nor the researchers know who receives the real drug or the placebo, reducing bias and ensuring objective results.
? Participants:
* 48 individuals with MCI or mild to moderate AD.
? Treatment Groups:
* Participants will be split into two groups: 24 will receive NTRX-07, and 24 will receive a placebo.
? Duration:
* The study will last up to 7-10 weeks for each participant, including a 28-day period during which they take the drug or placebo daily.
4. Study Procedures
? Screening Period:
* Before starting the treatment, participants will undergo a screening period of up to 45 days. During this time, they will have tests to confirm their eligibility, including physical exams, blood tests, cognitive assessments, and brain imaging (MRI).
? Treatment Period (28 days):
* Participants will take the study drug or placebo daily for 28 days. During this period, they will visit the study center for evaluations, including safety checks, cognitive tests, blood and CSF sampling, and EEG tests (to measure brain activity).
? Follow-Up:
* After the treatment period, participants will have a follow-up visit 7 days later for final safety assessments.
5. Safety Monitoring and Assessments
* The study's primary focus is on safety. Researchers will monitor participants closely for any adverse events, such as side effects, throughout the study.
* Safety assessments will include monitoring vital signs (blood pressure, heart rate, temperature), conducting laboratory tests (blood and urine analysis), performing physical examinations, and using electrocardiograms (ECGs) to monitor heart health.
6. Exploratory Assessments
? Although this study primarily focuses on safety, researchers will also conduct exploratory assessments to observe any potential positive effects of NTRX-07 on brain function and symptoms of AD. These will include:
o Cognitive Testing:
* Standard tests like the AD Assessment Scale-Cognitive Subscale (ADAS-cog) and the Mini-Mental State Examination (MMSE) will be used to evaluate any changes in cognitive function.
o Brain Imaging:
* MRI scans will help assess changes in brain structure and inflammation.
o Biomarkers:
* Blood and CSF samples will be analyzed for specific biomarkers related to inflammation, brain health, and AD progression.
7. Eligibility Criteria
* Inclusion Criteria:
* Individuals aged 65-88 with a confirmed diagnosis of MCI or mild to moderate AD.
* Must have a caregiver who can assist with the study requirements.
* Must be able to undergo specific procedures like MRI scans and CSF sampling.
* Exclusion Criteria:
* Individuals with other significant health conditions or history of neurological disorders other than AD.
* Those currently participating in another clinical trial or have certain medication restrictions.
8. Importance of the Study AD is a progressive condition that affects memory, thinking, and behavior. Current treatments only manage symptoms temporarily, and there is an need for new therapies. NTRX-07 is a novel drug that has shown promise in animal studies, potentially reducing brain inflammation, clearing harmful proteins, and improving memory and learning. This study is an essential step toward understanding if NTRX-07 can offer a safe and effective treatment option for people with AD.
9. Summary This clinical trial is designed to test the safety and processing of a new drug, NTRX-07, in people with MCI or mild to moderate AD. Participants will be carefully monitored for any side effects while researchers also gather data on the drug's impact on brain function. If successful, this study could lead to more advanced trials and, ultimately, a new treatment option for those affected by AD.

Start Date01 Mar 2025

Sponsor / Collaborator

NeuroTherapia, Inc.

[+1]

NCT06194552

/ CompletedPhase 1

A Multiple Ascending Dose, Phase 1, Double-Blind, Study to Investigate the Safety and Pharmacokinetics of NTRX-07 in Healthy Volunteers and Patients With Early Alzheimer's Disease (AD), With an Exploratory Fed-Fasted Assessment

This is a Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Multiple Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers and Subjects with MCI or Early AD. In addition, an exploratory study of the effect of a high fat meal was conducted.

Start Date06 Sep 2022

Sponsor / Collaborator

NeuroTherapia, Inc.

100 Clinical Results associated with NTRX-07

100 Translational Medicine associated with NTRX-07

100 Patents (Medical) associated with NTRX-07

Literatures (Medical) associated with NTRX-07

01 Jan 2024·Gastroenterology and hepatology from bed to bench

The investigation of the death-inducing potency of a recombinant Adenovector expressing Mda-7-tlyp-1 on different cancer cell lines.

Article

Author: Vatanparast, Fatemeh ; Farmani, Zahra ; Ghojoghi, Rozita ; Sarvari, Jamal ; Rastegari, Mahroo ; Hosseini, Seyed Younes ; Nekooei, Fatemeh ; Kadkhodazadeh, Maryam ; Jamali, Fatemeh ; Baesi, Kazem

Aim:

The potency of Adenovector expressing Mda7-tLyp1 (Ad-Mda7-tLyp1) for death induction was evaluated on the breast (MCF7), liver (HepG2), and gastric (MKN45) cancer cell lines.

Background:

Mda-7 could be a possible complementary to traditional cancer therapy, and tethering to tumor-homing peptides (THPs) might improve its therapeutic efficacy.

Methods:

After the preparation of recombinant Ad-Mda7-tLyp1 and Ad-Mda7, the expression of recombinant proteins was analyzed by ELISA. Adenovectors were transduced (MOI=2-5) into Hep-G2, MCF7, MKN45, and normal skin fibroblast, then tumor-killing effect was measured by cytopathic effect (CPE) monitoring, MTT viability test, BAX gene expression analysis, and Caspase3/7 assay.

Results:

ELISA assay revealed a sustained level of recombinant protein secretion following Adenovector transduction. In CPE microscopy, all cancer cell lines showed a significant reduction (≥50%) in their normal phenotype after receiving Ad-Mda7-tLyp1 and Ad-Mda7. The viability was significantly lower compared to the control, indicating an anti-proliferating effect. In parallel, the viability test showed that Ad-Mda7 and Ad-Mda7-tLyp1 have a significant killing effect (≥50%) on MCF-7, Hep-G2, and MKN45 compared to normal fibroblast (P≤0.05). BAX gene expression analysis showed that both Ad-Mda7-tLyp1 and Ad-Mda7 vectors induced >2-fold increase of apoptosis (P<0.05), particularly in MCF7. Similarly, caspase3/7 activity showed a significant increase (P<0.05) following Ad-Mda7, and Ad-Mda7-tLyp1 transduction into cancer cell lines, but not in normal fibroblasts.

Conclusion:

The newly constructed Ad-Mda-tlyp1 showed a suitable tumor cell killing activity and enough specificity on studied cell lines.

01 May 2019·The journal of pain : official journal of the American Pain Society

Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats

Article

Author: Bie, Bihua ; Hocevar, Mark ; Foss, Joseph F ; Naguib, Mohamed ; Wu, Jiang

Paclitaxel induces microglial activation and production of proinflammatory mediators in the dorsal horn, which contribute to the development and maintenance of central sensitization and pain behavior. MDA7, 1-([3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl]carbonyl) piperidine, is a novel highly selective cannabinoid type 2 (CB2) agonist. We tested the hypothesis that activation of CB2 receptor by MDA7 modulates microglial dysregulation, suppresses the overexpression of brain-derived neurotrophic factor (BDNF) in microglia in the dorsal horn, and attenuates the central sensitization and pain behavior induced by paclitaxel. For 4 consecutice days, groups of rats randomly received saline or 1.0 mg/kg of paclitaxel daily intraperitoneally for a total cumulative dose of 4 mg/kg. MDA7 15 mg/kg intraperitoneally or vehicle were administered 15 min before administering paclitaxel for 4 days and then continued for another 10 days. Behavioral and molecular studies were performed. Paclitaxel induced the expression of CB2 receptors and production of interleukin (IL)-6 in microglia in the dorsal horn. MDA7 attenuated the expression of IL-6 and promoted the expression of IL-10. Paclitaxel induced epigenetic upregulation of IRF8 and P2X purinoceptor 4 (P2X4) in microglia and subsequently increased the expression of alpha isoform of calcium/calmodulin-dependent protein kinase II (CaMKIIα), transcriptional factors p-CREB and ΔFosB, leading to the overproduction of BDNF in microglia. Paclitaxel also upregulated the expression of glutamate receptor subunits GluR1 and NR2B, decreased the expression of K⁺-Cl^- cotransporter, and induced mechanical allodynia in rats. All of the aforementioned molecular changes were attenuated by MDA7. Our data show that MDA7 attenuated paclitaxel-induced molecular and behavioral changes in rats. Perspective: This study provides evidence that paclitaxel induced microglia dysregulation and epigenetically upregulated the microglial expression of BDNF, which led to sensitization of dorsal horn neurons and mechanical allodynia in rats. The CB2 agonist MDA7 alleviated these pathological processes. MDA7 represents an innovative therapeutic approach for treatment of chemotherapy-induced neuropathy.

01 Sep 2017·European journal of pharmacologyQ3 · MEDICINE

Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer's disease

Q3 · MEDICINE

Article

Author: Mohamed Naguib ; Bihua Bie ; Joseph F. Foss ; Mark Hocevar ; Jiang Wu

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by neuroinflammation, extensive deposits of amyloid-β aggregates, and loss of memory and cognitive abilities. The brains of patients with AD show increased expression of cannabinoid receptor type 2 (CB₂) receptors and glial markers. CB₂ receptors act as a negative feedback regulator; when activated by a CB₂ agonist, they can help limit the extent of the neuroinflammatory response and the subsequent development of neuronal damage in the central nervous system. In a double transgenic APP/PS1 mice model of AD, we evaluated the effect of MDA7, a CB2 agonist, on several neuropathological conditions of AD including amyloid deposition, inflammatory reaction, Sox2 (sex-determining region Y-box 2) expression, and spatial memory. Activation of microglia CB₂ receptors by MDA7 suppressed neuroinflammation, demonstrated by decreased immunosignal of Iba1 in the hippocampal CA1 and dentate gyrus (DG) areas, promoted clearance of amyloid plaques in the DG area, restored Sox2 expression, and promoted recovery of the neuronal synaptic plasticity in hippocampal CA1. In addition, treatment with MDA7 improved the behavioral performance in the Morris water maze in APP/PS1mice. Collectively, these findings suggest that MDA7 has a potential therapeutic effect in the setting of AD.

News (Medical) associated with NTRX-07

13 Jul 2026

·www.prnewswire.com

NeuroTherapia to Present Phase 2a Alzheimer's Disease Clinical Data at the AAIC 2026 Conference in London, UK

Encouraging Data Demonstrating Target Engagement will be Presented in a Poster on Monday July 13ᵗʰ CLEVELAND, July 13, 2026 /PRNewswire/ -- NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, will be presenting data from its recently completed Phase 2a clinical trial in Alzheimer's Disease (AD) at the Alzheimer's Association International Conference (AAIC) 2026 during the Monday July 13th poster session. The trial was a 28-day, multicenter, randomized, double-blind, placebo-controlled study designed primarily to evaluate the safety, tolerability, and pharmacokinetics of NTRX-07 in 48 participants with mild cognitive impairment or mild-to-moderate AD, randomized 1:1 to NTRX-07 (90 mg/day) or placebo. The study also included a set of pre-specified exploratory biomarkers, neuroimaging, and cognitive endpoints intended to characterize pharmacodynamic activity and to inform the design of future controlled trials. In preclinical AD models, NTRX-07 was shown to modulate neuroinflammation, promote amyloid clearance, and improve neuronal function. To explore whether comparable pharmacodynamic activity could be observed in patients, the Phase 2a study evaluated diffusion MRI and cerebrospinal fluid (CSF) biomarkers. Diffusion MRI was used as an exploratory measure of neuroinflammation and neurodegeneration. Across several brain regions, descriptive analyses favored the NTRX-07 group on measures of neuroinflammation, with some areas showing statistically significant changes and other demonstrating directionally consistent trends toward reduced neurodegeneration. In an exploratory analysis within the treated arm, participants classified as responders showed patterns distinguishing them from non-responders on regional neuroinflammation and neurodegeneration measures, most notably in the superior parietal region — a region previously reported to show a strong correlation between the microglial marker sTREM2 and a diffusion-MRI measure of neuroinflammation (Ridgeway et al., 2024, CTAD, conference abstract). These observations warrant confirmation in a larger controlled study. The neuroimaging observations were accompanied by directionally consistent CSF biomarker patterns. Neurofilament light chain (NfL) remained stable or decreased in the NTRX-07 group while increasing in the placebo group over the 28-day period, and the Aβ42/Aβ40 ratio showed a within-group increase following NTRX-07 treatment, a pattern consistent with altered amyloid dynamics. Descriptive analyses also indicated a treatment-associated reduction in neuroinflammatory biomarkers, including IL-6 and YKL-40. These findings support the anti-inflammatory mechanism of NTRX-07 and will guide subsequent trials. "We are encouraged that NTRX-07's safety and pharmacokinetic profile was confirmed in AD patients, and that the exploratory biomarker and imaging signals point in a direction consistent with the anti-neuroinflammatory activity we observed in animal models," said Dr. Joseph Foss, NeuroTherapia's Chief Medical Officer. "I look forward to presenting the full dataset at AAIC in London." NTRX-07 was safe and well tolerated over the 28-day treatment period and drug exposure levels were consistent with the target range established in previous studies. "With a clean safety profile and pharmacodynamic signals consistent with our mechanism, we are excited to advance NTRX-07 into the next stage of controlled clinical development in AD," added Tony Giordano, Ph.D., the Company's CEO. "By showing pharmacodynamic activity relevant to neuroinflammation in human disease, we also see potential to explore NTRX-07 across other neuroinflammatory conditions." NTRX-07 is a small, orally available molecule that selectively activates CB2, which in turn drive microglia (key immune cells in the brain) into an anti-inflammatory state in diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and chronic pain syndromes. In various animal models of AD, NTRX-07 restored normal function of the microglia, which in turn decreased microglial-induced inflammation, reduced levels of the Alzheimer's-associated Ab peptide in the brain, and substantially improved neuronal synaptic plasticity, learning, and memory. This study was being funded in part by a grant from the Alzheimer's Association Part the Cloud program.1 About NeuroTherapia At NeuroTherapia, our mission is to develop treatments that will improve the course of the most debilitating and deadly central nervous system (CNS) diseases patients and their families face today. NeuroTherapia, Inc. is a clinical-stage, privately held biotechnology company, spun out of the Cleveland Clinic, developing oral, small-molecule drugs to address neuroinflammatory conditions of the CNS, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other CNS disorders. There is an emerging consensus that neuroinflammation plays a significant role in CNS disease. NeuroTherapia is a leader in developing novel therapeutics that modulate microglial activity, impacting the expression of proteins that drive inflammation in the CNS, thereby improving neuronal function and survival. Additional information about NeuroTherapia can be found at . ↩ SOURCE NeuroTherapia, Inc. 21% more press release views with Request a Demo

Phase 2Clinical Result

07 Apr 2026

·www.biospace.com

NeuroTherapia announces completion of its Phase 2a Trial of a novel treatment for Alzheimer’s Disease

Trial Designed to Demonstrate Target Engagement, Safety, and Pharmacokinetics CLEVELAND , April 7, 2026 /PRNewswire/ -- NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, has completed its Phase 2a clinical trial in Alzheimer's Disease (AD) patients. NTRX-07, the Company's lead molecule, was administered for 28 days in this double-masked, randomized clinical trial. In addition to monitoring safety, pharmacokinetics, and standard measures of clinical efficacy (ADAS-cog, MMSE, and Trail Making Test), the trial was designed to assess target engagement by analyzing biomarkers of neuroinflammation and neuronal function. "We are pleased to see that NTRX-07 continues to be safe and well tolerated in patients with Alzheimer's Disease, and that drug exposure levels were in line with what we expected, demonstrating a positive outcome," commented Dr. Joseph Foss, the company's Chief Medical Officer. "Following the preliminary analysis of the exploratory endpoints, the study met its core Phase 2a objectives and produced a positive multi-domain signal package across safety, PK, biomarkers, MRI, EEG, and clinical outcomes. This supports confidence in the further development of this new approach to treating Alzheimer's Disease." The primary objective of the study, safety and tolerability, was achieved, with overall Adverse Events (AEs) similar across the treatment and placebo groups. No treatment related Serious Adverse Events (SAEs) were reported in the active arm. Preliminary analysis of exploratory endpoints, including MRI, qEEG, and CSF biomarkers, indicates some encouraging results. Preliminary MRI findings, based on the hypothesis that neuroinflammation is important in AD progression, were directionally supportive, with changes trending toward stabilization on active treatment. Based in part on these encouraging results, NeuroTherapia is continuing to work with Oxford Brain Diagnostics Ltd on a more thorough analysis of the MRI data, including utilizing its CDM Explore platform to compare MRI results with changes in neuroinflammatory biomarkers, qEEG, and cognitive test results. The trial was managed by CRU Global, a leading European CRO, and conducted at sites in Hungary, Poland, and the Czech Republic. The trial enrolled 48 subjects in a 1:1 randomized design across five sites. "We were very pleased with the recruitment efforts at the sites, allowing the trial to complete on time. There was also considerable interest in participating in future trials expressed by site PIs, patients, and caregivers," commented Peter Kovacs, Ph.D., the President of CRU Global. "We are looking forward to working with NeuroTherapia on its next Phase 2 study, which we believe has an excellent opportunity to show clinical benefits to AD patients." NTRX-07 is a small orally available molecule that targets receptors that increase in diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and chronic pain syndromes. In various animal models of AD, NTRX-07 restored normal function of the microglia (key immune cells in the brain), which in turn decreased microglial-induced inflammation, reduced levels of the Alzheimer's-associated A ß peptide in the brain, and substantially improved neuronal synaptic plasticity, learning, and memory. This study was being funded in part by a grant from the Alzheimer's Association Part the Cloud program. About NeuroTherapia At NeuroTherapia, our mission is to develop treatments that will improve the course of the most debilitating and deadly central nervous system (CNS) diseases patients and their families face today. NeuroTherapia, Inc. is a clinical-stage, privately held biotechnology company, spun out of the Cleveland Clinic, developing oral, small-molecule drugs to address neuroinflammatory conditions of the CNS, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other CNS disorders. There is an emerging consensus that neuroinflammation plays a significant role in CNS disease. NeuroTherapia is a leader in developing novel therapeutics that modulate microglial activity, impacting the expression of proteins that drive inflammation in the CNS, thereby improving neuronal function and survival. Additional information about NeuroTherapia can be found at . View original content to download multimedia: SOURCE NeuroTherapia, Inc.

Phase 2Clinical Result

06 Aug 2024

·www.prnewswire.com

NeuroTherapia Raises $12.3M in the First Close of its Series B Financing

Investment will allow NeuroTherapia to continue the development of an orally available treatment for Alzheimer's disease. CLEVELAND, Aug. 6, 2024 /PRNewswire/ -- NeuroTherapia, Inc., a clinical-stage company and Cleveland Clinic Innovations portfolio company focused on developing therapies for neurodegenerative diseases, announced today the first closing of its Series B financing with $12.3M in funding. The Series B round, led by Cleveland Clinic, includes all previous investors, Brain Trust Accelerator Fund II, Dolby Family Ventures and the Alzheimer's Drug Discovery Foundation (ADDF) as well as new investors, Foundation for a Better World and CRUINT. NeuroTherapia is using this funding primarily for the continued clinical development of NTRX-07, an orally available cannabinoid receptor agonist, for the treatment of Alzheimer's disease (AD). The company will continue to raise additional funds for its second close in six months, which will enable development of a recently discovered second generation molecule for a separate indication in which neuroinflammation plays a major role. "We were pleased with the Phase 1b trial results that demonstrated a trend toward cognitive benefits in Alzheimer's disease and wanted to continue its development as rapidly as possible," commented Joseph Rich, JD, MBA, Senior Director, Cleveland Clinic Innovations, and lead investor representative in this financing. "We believe that the Company's planned Phase 2a trial has the potential to not only demonstrate the ability of NTRX-07 to inhibit neuroinflammation, but it could also lead to an improvement in biomarkers of cognitive function in patients with Alzheimer's disease." Coincident with the financing, the company welcomes Adam Hoffman to its Board of Directors as an Observer. Mr. Hoffman is an experienced investor and entrepreneur, currently serving as President of Foundation for a Better World. Mr. Hoffman joins Mr. Reher, who will continue to serve as Chairman of the Board, Tony Giordano, Ph.D., NeuroTherapia's President and CEO, and Joseph Rich and Jim Ellis from Cleveland Clinic and Akhil Saklecha, M.D., the CSO at Danaher, on the Board. In addition, Meriel Owen, Ph.D., Director of Search and Evaluation at the ADDF, serves as an Observer. "We are extremely fortunate to have the continued support of our previous investors and to add new investors with significant AD experience," said Dr. Giordano. "The Board has provided invaluable insights over the past 4+ years and I am excited to continue to work with them to advance NTRX-07 for treating AD." In addition to the Phase 2a trial, NeuroTherapia will use funding from this financing to study NTRX-07 in a preclinical model of ARIA (a significant side effect observed with administration of therapeutic monoclonal antibodies) in combination with therapeutic monoclonal antibodies. Based on its mechanism of action, NTRX-07 may reduce or prevent the ARIA side effect associated with monoclonal antibody treatment and/or improve the benefits of these therapies. A demonstration of activity in the preclinical ARIA study could lead to subsequent trials where NTRX-07 is used in combination with the therapeutic monoclonal antibodies to provide additional patient benefits. The company has also identified second-generation molecules that will be advanced for other indications associated with increased neuroinflammation, such as pain, Parkinson's disease or ALS. About NeuroTherapia NeuroTherapia is a clinical-stage, privately held biotechnology company developing oral, small-molecule drugs to address neuro-inflammatory conditions of the central nervous system (CNS), including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other CNS conditions. There is an emerging consensus that neuroinflammation plays a significant role in CNS disease. NeuroTherapia is developing therapeutics that inhibit microglia cells, which are known to express proteins that drive inflammation in the CNS, without affecting the clearance of toxic beta amyloid. We believe this approach will result in improved neuronal function and survival. At NeuroTherapia, our mission is to change the course of the most debilitating and deadly CNS diseases that patients and their families face today. Additional information about NeuroTherapia can be found at . About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $290 million to fund over 750 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 20 countries. To learn more, please visit: . SOURCE NeuroTherapia, Inc.

Phase 2Phase 1Executive Change

100 Deals associated with NTRX-07

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 2	Czechia	NeuroTherapia, Inc.	01 Mar 2025
Alzheimer Disease	Phase 2	Hungary	NeuroTherapia, Inc.	01 Mar 2025
Alzheimer Disease	Phase 2	Poland	NeuroTherapia, Inc.	01 Mar 2025
Neuroinflammation	Phase 1	Hungary	NeuroTherapia, Inc.	11 Dec 2025
Neuralgia	Phase 1	United States	NeuroTherapia, Inc.	10 Oct 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis